Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Global Drug Development International Collaboration: Overview: PIC/S
June 23, 23, 2014

Name: CARMELO ROSA, M.S., Psy.D.
Title: Director, Division International Drug Quality
Organisation: US FDA, CDER-OC, OMPQ
 Agenda

General Overview International Collaboration Initiatives

CDER-OC/OMPQ/DIDQ core functions related to our global interaction with international regulators

General Overview PIC/S

Conclusions
Ongoing USFDA-DIDQ Pilots and Programs

Active Pharmaceutical Ingredient (API) Program

- ICH Q7 as common guidance for API inspections
- Scope limited to third country sites (sites not in the home jurisdiction of the participating agencies)
- Routine exchange of GMP inspection reports since 2009
- Joint Inspections conducted since 2009
- Regular monthly teleconferences since 2010
- Led to increased communication, transparency and established processes for further collaboration, including drug shortages, regulatory action notification, and drug application compliance decisions

Precedent-setting Collaboration:

- In early 2012, FDA relied upon an EDQM inspection and subsequent Ph.Eur. Certificate suspension to take regulatory action (adding a firm to Import Alert 66-40); similar actions followed in 2012 and to present.

Participants

- FDA
- European Medicines Agency (EMA)
- European Directorate for the Quality of Medicines (EDQM)
- Australia’s Therapeutic Goods Administration (TGA)
- Italian Medicines Agency (AIFA)
- Irish Medicines Board (IMB)
- UK Medicines and Healthcare Products Agency (MHRA)
- Danish Medicines Agency (DKMA)
- French Medicines Agency (ANSM)
- World Health Organization (WHO)

1 Reference Document: API Program- Terms of Reference
Ongoing USFDA-DIDQ Pilots and Programs

Finished Dosage Pilot\(^2\) and Mutual Reliance Pilot (FDA/EMA)\(^3\)

- “Sister” pilots to focus first on confidence building via joint GMP inspections of finished dosage manufacturing sites (Finished Dosage Pilot) and then moving to reliance upon inspection information provided (Mutual Reliance Pilot) for regulatory decision making
- Joint inspections of finished dosage manufacturing sites in each other’s territory only (US and EU) began in 2010
- Exchange of inspectional information in order to defer/waive inspections based on risk analysis began in 2011
- Goal is to build confidence in respective inspection programs to reduce FDA inspections in EU and reduce EMA/Member State inspections in the US, thereby enabling a shift in inspectional resources to other regions

\(^2\) Reference Document: FD Pilot- General Principles
\(^3\) Reference Document: Mutual Reliance- General Principles
Ongoing USFDA-DIDQ Pilots and Programs

**Regulatory Cooperation Council GMP Pilot (FDA/Health Canada)**

- Part of larger White House Directive on US-Canada collaboration efforts in many industries – transportation, agriculture, environment, health and personal care products
- FDA’s 3 initiatives:
  - Common Electronic submissions
  - Common OTC monographs
  - *Mutual reliance on routine GMP inspection reports*
- 18-month initiative to increase reliance on GMP inspection reports for risk-based firms of common interest in US and Canada
- Timeline: May 2012 – December 2013
  - Final public webinar held in May 2014
- Activities include sharing/comparison of inventory and observational inspections

---

4 Reference Document: [RCC- White House Directive](#)
FDA and PIC/S

Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) mission: “…to facilitate the networking between participating authorities and the maintenance of mutual confidence, the exchange of information and experience in the field of GMP and related areas, and the mutual training of GMP inspectors.”

FDA granted PIC/S membership in January 2012

Current USFDA involvement with PIC/S Activities

• Prior knowledge and review of revisions to EU GMP regulations and PIC/S Guidances for industry
• Sharing of Inspection Planning with all PIC/S members
• Common Inspection Report Template to all PIC/S members
• Joint and Coached Inspection Training exercises
• Participation in “Expert Circle” groups, training, and discussions
• Co-chair of API Expert Circle, currently focusing on training opportunities in South Africa, Latin America, China and India

PIC/S website: www.picscheme.org
Foreign Regulatory Authority Review in CMS

• Based on Non-Compliance Reports (NCRs) and alerts received from foreign regulatory agencies, inspection reports may be requested (generally top reason for request)
Welcome to EudraGMDP

EudraGMDP is the name for the Union database referred to in article 11(1)(b) of Directive 2001/83/EC and article 8(3) of Directive 2001/83/EC. It contains the following information:

- Manufacturing and import authorizations
- Good Manufacturing Practice (GMP) certificates
- Statements of non-compliance with GMP
- GMP inspection planning in third countries

In addition, the following new information is required in the database for the first time in 2013. As data transfer from national systems can be complex, it will take several months for all the National Competent Authorities to complete the uploading of this data:

- Wholesale Distribution Authorizations
- Good Distribution Certificates (GDP)
- Statements of non-compliance with GDP
- Registration of manufacturers, importers and distributors of active substances for human use located in the EEA

Almost all information uploaded into the database is available to the general public. National Competent Authorities are able to exclude some information from public view. This includes information of a commercially sensitive or personal nature, inspection planning and information that may need to be restricted in the interests of security.

Read-only access to EudraGMDP

Access to EudraGMDP application for registered users.

Users are advised that since inspections of manufacturers of active substances are based on risk, some active substance manufacturers may not be in possession of a GMP certificate issued by an EEA authority. The absence of a GMP certificate should not be understood as meaning that the active substance manufacturer in question does not comply with GMP.

EMA is not responsible for the contents of the database. Any questions on its content should be addressed to the relevant National Competent Authority.
Welcome to EudraGMDDP


The concept of a European Inspections database is included in the above specified legislation to provide EEA National Competent Authorities and the European Medicines Agency (EMA) with an overview of the status of pharmaceutical manufacturers. The legislation provides for an electronic tool containing complete information on all pharmaceutical manufacturers. This includes information on Manufacturing and Importation Authorisations (MIA) and Good Manufacturing Practice (GMP) Certificates for authorised sites in the EEA and information on GMP certificates for manufacturers in third countries.

Compliance with Good Manufacturing Practice:

A certificate of Good Manufacturing Practice (GMP) is issued to a manufacturer by the national competent authority that carried out an inspection if the outcome of the inspection confirms that the manufacturer complies with the principles of Good Manufacturing Practice, as provided by European Union legislation. If the outcome of the inspection is that the manufacturer does not comply a statement of non-compliance may be entered into EudraGMDDP. Certificates and statements of non-compliance may be issued to manufacturers of medicinal products and manufacturers of active substances located inside and outside of the European Union.

Manufacturing and Importation Authorisation:

Manufacture of medicinal products in the EU or importation from a third country is subject to the holding of a Manufacturing and Importation Authorisation. The National Competent Authority of the Member State in which the manufacturer or importer operates issues these authorisations.

Compliance with Good Distribution Practice:

A certificate of Good Distribution Practice (GDP) is issued to a wholesale distributor by the national competent authority that carried out an inspection if the outcome of the inspection confirms that the wholesale distributor complies with Good Distribution Practice, as provided by European Union legislation. If the outcome of the inspection is that the wholesale distributor does not comply a statement of non-compliance may be entered into EudraGMDDP. GDP certificates and statements of non-compliance may be issued to wholesale distributors of medicinal products and distributors of active substances.

Wholesale Distribution Authorisation:

The wholesale distribution of medicinal products is subject to the holding of a Wholesale Distribution Authorisation. The National Competent Authority of the Member State in which the wholesale distributor operates these authorisations.

Registration of Active Substance manufacturers, Importers and Distributors:

Manufacturers, importers and distributors of active substances are required to register their activities with the National Competent Authority of the Member State in which they operate.

The EudraGMDDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage) if it should occur due to you (or any other third party) relying on or in any way depending on the information on this database. Any questions about the content should be addressed to the relevant NCA. Please see here to get list of NCAs.

[Boilerplate: EMA & EudragMDP 4.1.2.1 build 2514-053-14 17-01-2011]
### GMP Non-Compliance Search Results - 8 Items

<table>
<thead>
<tr>
<th>Report Number</th>
<th>Site Name</th>
<th>City</th>
<th>Country</th>
<th>Postcode</th>
<th>DUNS Number</th>
<th>EudraGMDP Key</th>
<th>NCA Ref</th>
<th>MIA Number</th>
<th>Issue Date</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK GMP 31450 Imp GMP 31450/303311-0005 NCR</td>
<td>IND-SWIFT LIMITED</td>
<td>DISTRICT SAS NAGAR (MOKHALI)</td>
<td>India</td>
<td>PIN-140507</td>
<td>8787</td>
<td>360311-IND-SWIFT LIMITED</td>
<td></td>
<td></td>
<td>2014-03-21</td>
<td>ngrewal (UK_MHRA)</td>
</tr>
<tr>
<td>14MP024</td>
<td>SOMET</td>
<td>MONACO</td>
<td>Monaco</td>
<td>98000</td>
<td>9170</td>
<td>A067 6922 597</td>
<td></td>
<td></td>
<td>2014-03-05</td>
<td>granud (FR_ANISM)</td>
</tr>
<tr>
<td>13MP067</td>
<td>Smruthi Organics Limited</td>
<td>Taluka Mohol</td>
<td>India</td>
<td>413 255 Solapur, Maharashtra</td>
<td>15103</td>
<td>151031360840861198</td>
<td></td>
<td></td>
<td>2014-01-08</td>
<td>spilema (NL_IGZ)</td>
</tr>
<tr>
<td>suulis186744/2013</td>
<td>VAKOS XT a.s.</td>
<td>Prague 8</td>
<td>Czech Republic</td>
<td>186 00</td>
<td>3035</td>
<td>25656180_1</td>
<td>suulis53410/2013</td>
<td></td>
<td>2014-02-24</td>
<td>haclavskova (CZ_SUGK)</td>
</tr>
<tr>
<td>91314-013V2</td>
<td>INDUSTRIAS GMBH, S.A.</td>
<td>Castellbisbal</td>
<td>Spain</td>
<td>08765</td>
<td>23346</td>
<td>233481391590600821</td>
<td></td>
<td></td>
<td>2014-02-10</td>
<td>metamo (ES_AEMPIS)</td>
</tr>
<tr>
<td>13/13256-14</td>
<td>Suzhou No. 4 Pharmaceutical Factory</td>
<td>Suzhou</td>
<td>China</td>
<td>210 008</td>
<td>22767</td>
<td>227671385194259413</td>
<td></td>
<td></td>
<td>2013-12-06</td>
<td>bozhen (NO_NOIMA)</td>
</tr>
</tbody>
</table>
Medicines and Healthcare Products Regulatory Agency

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer. (1)

Part 1

Issued following an inspection in accordance with:
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer: IND-SWIFT LIMITED
Site address: OFF NH-21 VILLAGE JAWAHARPUR, TEHSIL DERA BASSI, DISTRICT SAS NAGAR (MOHALI), PUNJAB, PIN-140607, India

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2013-10-23, it is considered that it does not comply with the Good Manufacturing Practice requirements referred to in

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC (2)

(1) The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

Part 2

Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS
1.2 Non-sterile products
Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS

1.1 Sterile products

1.1.1 Aseptically prepared (processing operations for the following dosage forms)
   1.1.1.1 Large volume liquids
   1.1.1.4 Small volume liquids

1.2 Non-sterile products

1.2.1 Non-sterile products (processing operations for the following dosage forms)
   1.2.1.6 Liquids for internal use

1.4 Other products or manufacturing activity

1.4.2 Sterilisation of active substance/ excipients/ finished product
   1.4.2.1 Filtration

1.5 Packaging

1.5.1 Primary Packing
   1.5.1.1 Capsules, hard shell
   1.5.1.13 Tablets

Part 3

Nature of non-compliance: 1. A critical deficiency was cited regarding potential product cross contamination, this deficiency was divided into two parts. A. Potential chemical contamination, it was found that the company were manufacturing a potent cytotoxic (Amsacrine) product in the non-potent suite. Processes intended to contain the product had failed and cleaning process and verification were weak with contamination of general manufacturing area seen. B. Potential microbial contamination. There were contaminated process media simulations that were not adequately investigated and root cause explained and mitigated. VHP sanitisation of the filling isolator inadequately controlled and validated and weaknesses in the environmental monitoring system. 2. A major deficiency regarding the change control program (not all changes were controlled appropriately) and investigations, which were poor in quality, regards to root cause analysis and corrective and preventative actions and were not performed in a timely manner. 3. A second major deficiency regarding maintenance of equipment and facilities with poor controls witnessed.

Action taken/proposed by the NCA:

Withdrawal, of current valid GMP certificate No. UK MIA 34140 Insp GMP/IMP 34140/113925-0006
A restricted GMP certificate will be issued to permit continued manufacture and testing of products considered to be medically critical, as determined by the competent authority.
Foreign Regulatory Authority Review in CMS

• Once received, NCRs are input into CMS through a work activity #
Foreign Regulatory Authority NCR Review in CMS
Foreign Regulatory Authority Review in CMS

- Request is sent to Foreign Regulator

CDER would like to request the April 22-26, 2013 inspection report, if available, from MHRA for the firm indicated below.

Micro Labs Limited
Plot No. 113-116 4th Phase KIADB
Bommasandra Industrial Area, Anekal Taluk
Bangalore, IN
FEI #2009310198

Thank you,

Lisa Tung
CDER Office of Compliance
Office of Manufacturing and Product Quality
Division of International Drug Quality
International Compliance Branch
Foreign Regulatory Authority Review in CMS

• Foreign Regulator sends back report if available

Dear Shena,

Please find the report attached.

Kind regards,
Jo

Joanna Milborrow
Inspection Services Executive
MHRA
55 Piccadilly, London, SW1X 8NP, UK
INSPECTION REPORT

Eisai Manufacturing Ltd.
European Knowledge Centre,
Mosquito Way,
Hatfield
AL10 9SN

Sentinel Case Folder:
Insp GMP/GDP/IMP 32301/726219-0004
Foreign Regulatory Authority Review in CMS

• DIDQ management will assign work activity to a Compliance Officer/Consumer Safety Officer for review.

• Some information will be pre-filled upon assignment, the rest is for your review.

• Ensure all dates, Foreign Agency, ‘triaging info’, application information (if applicable) outcome, GMP problems, documents, activity notes are completed.

• Ensure that the Foreign Reg Report Assessment Tool is filled out in Excel and uploaded to each Work Activity.
Foreign Regulatory Authority Review in CMS

- Once received, FRARs are input into CMS
Foreign Reg Report Review – Part 1
PIC/S Overview

- History of PIC/S and PIC
- Role & Functions of PIC/S
- PIC/S Accession Procedure
- PIC/S Guides & Recommendations
- PIC/S Seminars & Expert Circles
- PIC/S Quality Systems
History

PIC
Pharmaceutical Inspection Convention

PIC Scheme
Pharmaceutical Inspection Cooperation Scheme

Both operate in parallel under the logo/abbreviation
History

PIC = Pharmaceutical Inspection Convention

- Founded by The European Free Trade Association (EFTA) in October 1970
- PIC is a legal Treaty between countries
- Initially only 10 member countries: Austria, Denmark, Finland, Iceland, Liechtenstein, Norway, Portugal, Sweden, Switzerland and UK.
Original Goals

✓ Harmonised GMP requirements
✓ Mutual recognition of inspections
✓ Uniform inspection systems
✓ Training of Inspectors
✓ Mutual confidence
PIC membership as at January 1995

Pharmaceutical Inspection Convention
(a Treaty between countries below)

18 Member countries:

Australia, Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Liechtenstein, Norway, Portugal, Romania, Sweden, Switzerland, United Kingdom.
Reason for creating the PIC Scheme

- After 1993, no new members of PIC possible
- Reasons:
  - Under EU law, only European Commission authorised to sign agreements with other countries
  - Expansion of PIC not possible unless European Commission became a member of PIC
  - Amendment of Convention difficult & lengthy
  - Inspectorates (& industry) favoured maintaining the principles of PIC
- Consequently, the PIC Scheme was developed & implemented.
Main features of PIC Scheme

- Commenced operating on 2 Nov. 1995
- An informal arrangement between Agencies
- Networking and confidence building
- Exchange of information and experience on GMP
- Development of Quality Systems for Inspectorates
- Training of inspectors
- International harmonisation of GMP
- No obligation to accept inspection reports
- PIC & PIC/S operate in parallel - jointly referred to as “PIC/S”
PIC/S Goal

“To lead the international development, implementation and maintenance of harmonised GMP standards and quality systems of inspectorates in the field of medicinal products”.
Achievement of PIC/S Goal

PIC/S Goal to be achieved by:

✓ Developing and promoting harmonised GMP standards and guidance documents.
✓ Training competent authorities, in particular GMP inspectors.
✓ Assessing (and reassessing) GMP Inspectorates.
✓ Facilitating the co-operation and networking for competent authorities and international organisations.
46 PIC/S Members (as of 1 July 2014)

10 PIC/S Applicants & Pre-Applicants
## PIC versus PIC/S

<table>
<thead>
<tr>
<th>PIC</th>
<th>PIC/S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convention</td>
<td>Scheme</td>
</tr>
<tr>
<td>Between countries</td>
<td>Between agencies</td>
</tr>
<tr>
<td>A formal treaty</td>
<td>An informal arrangement</td>
</tr>
<tr>
<td>Has legal status</td>
<td>Has no legal status</td>
</tr>
<tr>
<td>Focus on inspection</td>
<td>Focus on training &amp; Developing guidelines</td>
</tr>
<tr>
<td>Mutual recognition of inspections</td>
<td>Exchange of information</td>
</tr>
</tbody>
</table>
Benefits of PIC/S Membership

✓ Accession forced improvements – i.e. discipline
✓ Cost saving – import control mechanism
✓ Facilitated exports of medicines
✓ Training (seminars, Joint Inspections, etc.)
✓ Involvement with developing international GMPs
✓ Facilitated MRA with EC
✓ Networking & personal contacts
How PIC/S operates

- PIC/S Committee
- Secretariat
- Executive Bureau: Chair, Deputy Chair, past Chair, seven Chairs of Sub-Committees
- Small Budget
- Good relationship and co-operation
- Training opportunities
- Exchange of information, rapid alerts
- Development of GMP guidelines
New PIC/S Organisational Sub-Committee Structure

To reply to PIC/S’s growing membership, a new Sub-Committee structure has been developed and come in force 1\textsuperscript{st} January 2014, in order to:

• Favour the participation of all PIC/S Participating Authorities

• Establish a more participative and efficient organisation of PIC/S, where each Sub-Committee will be responsible for its respective core areas and will take the lead in developing policies.
PIC/S new structure as of 1 January 2014

Most competences of the PIC/S Committee are delegated to Sub-Committees, which report back to the Committee.

PIC/S Committee

Plenary Meeting: operates PIC Scheme and takes decisions

Election of office holders & SC Members; Treaty power
Acceptance of new PA
Adoption of budget
Etc.

Sub-Committee on Compliance
Plans & reviews both assessments & reassessments

Sub-Committee on Strategic Development
Reviews PIC/S strategy & policies

Sub-Committee on Harmonisation of GM(D)P
Harmonises GM(D)P & establishes Best Practice

Sub-Committee on Communication
Defines communication strategy

Sub-Committee on Budget, Risk & Audit
Assesses all risks, reviews audits; prepares budget

Sub-Committee on Expert Circles
Reviews activities of Expert Circles

Sub-Committee on Training
Plans & reviews GMP Training
<table>
<thead>
<tr>
<th>Accession to PIC</th>
<th>Accession to PIC/S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>May 1971</td>
</tr>
<tr>
<td>Denmark</td>
<td>May 1971</td>
</tr>
<tr>
<td>Finland</td>
<td>May 1971</td>
</tr>
<tr>
<td>Iceland</td>
<td>May 1971</td>
</tr>
<tr>
<td>Liechtenstein</td>
<td>May 1971</td>
</tr>
<tr>
<td>Norway</td>
<td>May 1971</td>
</tr>
<tr>
<td>Portugal</td>
<td>May 1971</td>
</tr>
<tr>
<td>Sweden</td>
<td>May 1971</td>
</tr>
<tr>
<td>Switzerland</td>
<td>May 1971</td>
</tr>
<tr>
<td>UK</td>
<td>May 1971</td>
</tr>
<tr>
<td>Hungary</td>
<td>Aug 1976</td>
</tr>
<tr>
<td>Ireland</td>
<td>Dec 1977</td>
</tr>
<tr>
<td>Romania</td>
<td>May 1982</td>
</tr>
<tr>
<td>Germany</td>
<td>Sep 1983</td>
</tr>
<tr>
<td>Italy</td>
<td>Aug 1990</td>
</tr>
<tr>
<td>Belgium</td>
<td>Sep 1991</td>
</tr>
<tr>
<td>France</td>
<td>Dec 1992</td>
</tr>
<tr>
<td>Australia</td>
<td>Jan 1993</td>
</tr>
<tr>
<td>Netherlands</td>
<td>-</td>
</tr>
</tbody>
</table>
## Accessions dates (2)

<table>
<thead>
<tr>
<th>Accession to PIC</th>
<th>Accession to PIC/S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>-</td>
</tr>
<tr>
<td>Canada</td>
<td>-</td>
</tr>
<tr>
<td>Singapore</td>
<td>-</td>
</tr>
<tr>
<td>Greece</td>
<td>-</td>
</tr>
<tr>
<td>Malaysia</td>
<td>-</td>
</tr>
<tr>
<td>Latvia</td>
<td>-</td>
</tr>
<tr>
<td>Czech Rep (Vet)</td>
<td>-</td>
</tr>
<tr>
<td>Poland</td>
<td>-</td>
</tr>
<tr>
<td>Estonia</td>
<td>-</td>
</tr>
<tr>
<td>South Africa</td>
<td>-</td>
</tr>
<tr>
<td>Argentina</td>
<td>-</td>
</tr>
<tr>
<td>Malta</td>
<td>-</td>
</tr>
<tr>
<td>Cyprus</td>
<td>-</td>
</tr>
<tr>
<td>France (Vet)</td>
<td>-</td>
</tr>
<tr>
<td>Israel</td>
<td>-</td>
</tr>
<tr>
<td>Lithuania</td>
<td>-</td>
</tr>
<tr>
<td>USA</td>
<td>-</td>
</tr>
<tr>
<td>Ukraine</td>
<td>-</td>
</tr>
<tr>
<td>Slovenia</td>
<td>-</td>
</tr>
<tr>
<td>Indonesia</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Jan 1998</td>
</tr>
<tr>
<td></td>
<td>Jan 1999</td>
</tr>
<tr>
<td></td>
<td>Jan 2000</td>
</tr>
<tr>
<td></td>
<td>Jan 2002</td>
</tr>
<tr>
<td></td>
<td>Jan 2002</td>
</tr>
<tr>
<td></td>
<td>Jan 2003</td>
</tr>
<tr>
<td></td>
<td>Jul 2005</td>
</tr>
<tr>
<td></td>
<td>Jan 2006</td>
</tr>
<tr>
<td></td>
<td>Jan 2007</td>
</tr>
<tr>
<td></td>
<td>Jul 2007</td>
</tr>
<tr>
<td></td>
<td>Jan 2008</td>
</tr>
<tr>
<td></td>
<td>Jan 2008</td>
</tr>
<tr>
<td></td>
<td>Jul 2008</td>
</tr>
<tr>
<td></td>
<td>Jan 2009</td>
</tr>
<tr>
<td></td>
<td>Jan 2009</td>
</tr>
<tr>
<td></td>
<td>Jul 2009</td>
</tr>
<tr>
<td></td>
<td>Jan 2011</td>
</tr>
<tr>
<td></td>
<td>Jan 2011</td>
</tr>
<tr>
<td></td>
<td>Jan 2012</td>
</tr>
<tr>
<td></td>
<td>Jul 2012</td>
</tr>
</tbody>
</table>
## Accessions dates (3)

<table>
<thead>
<tr>
<th>Accession to PIC</th>
<th>Accession to PIC/S</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Zealand</td>
<td>-Jan 2013</td>
</tr>
<tr>
<td>Chinese Taipei</td>
<td>-Jan 2013</td>
</tr>
<tr>
<td>United Kingdom (Vet)</td>
<td>-Jan 2014</td>
</tr>
<tr>
<td>Japan</td>
<td>-Jul 2014</td>
</tr>
<tr>
<td>Korea (Republic of)</td>
<td>-Jul 2014</td>
</tr>
</tbody>
</table>
Applicants being assessed for membership

- Brazil / ANVISA
- Hong-Kong SAR / PPBHK
- Iran / MoH
- Philippines / PFDA
- Thailand / Thai FDA
- Turkey / TMMDA
Applicants for Pre-Accession

- Armenia / SCDMTE
- Belarus / MoH
- Chile / ISP
- Kazakhstan / CCMPA
- Mexico / COFEPRIS
Agencies showing interest in joining PIC/S

- China / CFDA
- Croatia / HALMED
- Nigeria / NAFDAC
- Russia / Roszdravnadzor
- Saudi Arabia / SFDA
- Thailand / Thai FDA
- Zimbabwe / MCAZ
Accession+ Pre-accession procedure

Useful Documents

- Pharmaceutical Inspection Cooperation Scheme (PIC/S 1/95)
- Guidelines for Accession to PIC/S (PS/W 14/2011)
- Questionnaire for Competent Authorities (PS/W 1/2011)
- Audit Checklist (PS/W 1/2005)
- Recommendations on quality system requirements for pharmaceutical inspectorates (PI 002)
1. Pre-accession procedure

- As some of the new applicants may have notable differences or are not familiar to PIC/S standards, a new “period” offers a “softer” approach and more time to adjust.

- It is a kind of pre-assessment and gap analysis of the Applicant Authority to the PIC/S requirements and a possible on site visit of an “auditor” appointed by the Committee.

- Time frame up to 2 years

- Then, time to decide for the application. Is the Applicant ready?

  The Committee will decide on the next steps (invitation to apply or further delay to prepare)
2. Accession procedure

Steps to Accession

- General interest & commitment, eg. attend Seminars
- Written application to Secretary + supporting documents
- PIC/S Committee appoints Rapporteur to evaluate
- Applicant invited to Committee meeting to answer questions of Rapporteur and Committee
- PIC/S delegation undertakes assessment visit (Inspectorate’s procedures; observe 3 or 4 inspections)
- Delegation report issued (to applicant & Committee)
- Committee decides on membership.
PIC/S GMP Guide

Virtually identical to EC GMP Guide
(main difference = “Qualified Person” vs. “authorised person”)

Basic GMP Guide (Part I)
GMP Guide for APIs (Part II)

Plus Annexes, covering:
- Sterile Medicinal Products
- Sampling of Starting Materials & Packaging Materials
- Pressurised Metered Dose Aerosols
- Liquids, Creams & Ointments
- Computerised Systems
- Radiopharmaceuticals
PIC/S GMP Guide (2)

Plus Annexes, covering:

- Biologicals
- Herbals
- Medicinal gases
- Use of Ionising Radiation
- Investigational Medicinal Products
- Products Derived from Human Blood & Plasma
- Qualification and Validation
- Parametric release
- Reference and Retention Samples
Development of GMP Guidance Documents

- Usually initiated at end of PIC/S Seminars
- PIC/S Working Group formed
- Author prepares draft
- Comments from Working Group
- Comments from PIC/S Inspectorates
- Comments from Industry
- Endorsed by PIC/S Committee for general distribution
- Simultaneous distribution by EMA (& vice versa)
PIC/S Works on Validation

- 1994 PIC Seminar in Ireland on Validation identified need to develop guidance document
- PIC/S Recommendations prepared covering:
  - Validation Master Plan
  - Installation & Operational Qualification (IQ & OQ)
  - Non-sterile Process Validation
  - Cleaning Validation
- PIC/S entry into force on 1st March 1999
- Adopted by the EU as Annex 15 to EU GMP Guide
Some PIC/S Recommendation & Guideline Documents

- PIC/S GMP Guide (similar to EU GMP Guide).
- Validation (master plan, IQ/OQ, process, cleaning).
- Validation of Aseptic Processes.
- Inspection of Isolator Technology.
- Quality Systems for Inspectorates.
- Sterility Testing.
- Validation of Computerised Systems.
PIC/S involvement in the ICH GMP Guide on APIs

- PIC/S Conference in Canberra 1996: consensus obtained to prepare international GMP.
- PIC/S draft document prepared during ‘97 & ‘98.
- ICH Q7 took over the work of PIC/S mid-1998 to enable industry to become involved:
  - ICH involves 3 regions (USA, Europe & Japan).
- ICH GMP Guide finalised in November 2000 after extensive public consultation.
- Most countries have adopted ICH document as a GMP requirement for APIs by 1st April 2001 (EU).
- ICH document became Part II of PIC/S GMP Guide in 2007
<table>
<thead>
<tr>
<th>Topic</th>
<th>Location</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packaging &amp; Labelling</td>
<td>Switzerland</td>
<td>1971</td>
</tr>
<tr>
<td>Contamination</td>
<td>Sweden</td>
<td>1972</td>
</tr>
<tr>
<td>Quality</td>
<td>France</td>
<td>1972</td>
</tr>
<tr>
<td>Sampling &amp; Analytical Control</td>
<td>UK</td>
<td>1973</td>
</tr>
<tr>
<td>Contract Manufacture &amp; QC</td>
<td>Switzerland</td>
<td>1974</td>
</tr>
<tr>
<td>QC Department</td>
<td>Denmark</td>
<td>1975</td>
</tr>
<tr>
<td>Stability</td>
<td>Austria</td>
<td>1976</td>
</tr>
<tr>
<td>Isolation/ID/Quantification of Drugs</td>
<td>Sweden</td>
<td>1977</td>
</tr>
<tr>
<td>Tablet Manufacture</td>
<td>UK</td>
<td>1978</td>
</tr>
<tr>
<td>Large Volume Parentericals</td>
<td>Norway</td>
<td>1978</td>
</tr>
<tr>
<td>PIC Basic GMP Guide</td>
<td>Finland</td>
<td>1979</td>
</tr>
<tr>
<td>(Need for Revision?)</td>
<td>Denmark</td>
<td>1980</td>
</tr>
<tr>
<td>Tablet Manufacture</td>
<td>Switzerland</td>
<td>1980</td>
</tr>
<tr>
<td>Manufacture of Active Ingredients</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PIC/S Seminars (2)

- Control Laboratory  Hungary, 1981
- Validation  Ireland, 1982
- Packaging  Portugal, 1983
- Production of Biological Products  Germany, 1984
- Premises  Norway, 1985
- Plastics  Sweden, 1986
- Inspection  UK, 1987
- Water  Switzerland, 1988
- Contamination Risk in the Manufacture of Parenterals  Austria, 1989
- Blood & Blood Products  Denmark, 1990
- Audit - Pharmaceutical Inspection  Hungary, 1991
- Products Derived from Biotechnology  Italy, 1992
PIC/S Seminars (3)

- Inspection & Testing in Relation to the Marketing Authorisation
- Qualification & Validation
- Manufacture of Sterile Products
- Computer Systems
- GMP Standards for APIs
- Manufacture & Inspection of APIs
- Quality Systems for Inspectorates
- Non-technical Aspects of Inspection
- Biotechnology
- Inspection of Utilities
- Interface between GCP and GMP

Belgium, 1993
Ireland, 1994
Iceland, 1995
Australia, 1996
Australia, 1996
Finland, 1997
Holland, 1998
UK, 1999
France, 2000
Czech Rep, 2001
Canada, 2002
PIC/S Seminars (4)

- Inspection of QC laboratories  Slovak Rep, 2003
- Inspection of APIs  Spain, 2004
- Primary packaging, labelling and prevention of mix-up  Romania, 2005
- Risk Management  Germany, 2006
- Solid Dosage Form Manufacturers  Singapore, 2007
- Good Distribution Practices  Poland, 2008
- Sterile Aseptic Manufacturing  Sweden, 2009
- Herbal / Traditional Medicines  Malaysia, 2010
- Good Inspection Practices  South Africa, 2011
- Qualification and Validation  Ukraine, 2012
- Global Supply Chains and GMP Compliance  Canada, 2013
Future PIC/S Seminar

- Dedicated Facilities or not?
  France, 2014
Expert Circles / Working Groups

✓ APIs
✓ Computerised Systems
✓ Human Blood, Tissues and Cells
✓ Quality Risk Management
✓ Good Distribution Practices

Aim: Develop draft guidance documents
Training in specialised field
PIC/S Joint Visits

- Started in 1987
- Around 25 groups of 3 inspectors from 3 countries
- 1 inspection per 6 months per country
- for training purposes
- for uniform GMP interpretation
- for uniform inspection procedures
- for mutual confidence
Relationship with EMA

- EMA attends PIC/S Committee as a Partner
- PIC/S-EU liaison officer attends Inspectors meetings at EMA as an observer
- A harmonised consultation procedure
- Associated Partnership negotiated in 2007 (renewed in 2010)
Liaison with other organisations

✓ The European Department for the Quality of Medicines (EDQM): Associated Partnership negotiated in 2007 (renewed in 2013),
✓ UNICEF: Associated Partnership negotiated in 2008,
✓ WHO: Co-operation Arrangement negotiated in May 2009
✓ ICH,
✓ European Commission (DG Health & Consumers)
Quality system requirements for pharmaceuticals inspectorates

- Reference document: PI 002-3

- Purpose: adopting a common standard for quality system requirements in order to achieve consistency in inspection standards between National Pharmaceutical Inspectorates and thus to facilitate mutual recognition of those Inspectorates
Quality system requirements for pharmaceuticals inspectorates

Main topics

- Quality Improvement and Corrective / Preventive Action
- Complaints
- Issue and Withdrawal of Licences and GMP certificates
- Handling Suspected Quality Defects and Rapid Alert System
- Liaison with OMCL
- Sub-Contracting and Assessing
Quality system requirements for pharmaceuticals inspectorates

Main topics

- Quality Manual
- Administrative Structure
- Organisation and Management
- Documentation and Change Control
- Records
- Inspection Procedures
- Inspection Resources
- Internal Audit
Joint Reassessment programme

Goals

❖ To verify that PIC/S member authorities maintain compliance with the requirements of the Scheme (as described in paragraph 8 of the Scheme [PIC/S 1/95 modified]).
❖ To verify the implementation of quality system requirements for pharmaceutical inspectorates.
❖ To help maintain consistency among PIC/S member authorities
Typical PIC/S Inspection of a Medicine Manufacturer

**Before the inspection:**

- Lead inspector assigned.
- Inspection team selected.
  - Technical specialist sometimes included on team
- Company notified.
  - Company requested to provide Site Master File (SMF)
- Inspection team reviews documentation.
  - SMF, complaints, recalls, testing failures, marketing authorisations.
- Lead inspector prepares inspection plan & sends to company.
- Inspection conducted.
Typical PIC/S Inspection of a Medicine Manufacturer (cont'd)

After the inspection:

- Caucus of inspection team.
- Interim inspection report prepared (deficiencies only).
- Exit interview with company:
  - Attendance sheet completed.
  - Interim inspection report provided (discussion encouraged).
  - Written response requested within 4 weeks.
- Objective evidence assessed by lead inspector.
- If response judged OK, inspection closed out.
- Final inspection report sent to company
- If response not OK, refer to Independent Committee for appropriate action.
PIC/S Inspection Report

• Identical to the EU Inspection Report format
• SOP for PIC/S Inspection Report format is available on PIC/S web site (document PI 013-3)
• This format used by PIC/S and EU Inspectorates to prepare GMP inspection reports
• Uniform system of classifying GMP deficiencies
  – “critical”, “major” & “other”
PIC/S Blueprint

- PIC/S Blueprint adopted by PIC/S Committee in December 2005

Aim:

- To review PIC/S’ mission & goals in a changing environment.
- To set a number of objectives and actions for the next 10 years.
- To raise PIC/S’ visibility and explain the benefits of PIC/S membership.
- To make PIC/S more of a global organisation rather than European focussed.

(PIC/S Blueprint is available at [www.picscheme.org](http://www.picscheme.org))
Recent Developments

- Accession of Japan’s MHLW, PMDA & Prefectures and of Korea’s MFDS (July 2014)
- New PIC/S GDP Guide, based on EU GDP Guide (June 2014)
- Revision of PIC/S GMP Guide (Part II of GMP Guide (Q7A), Annex 2 and 14) (March 2014)
- New PIC/S Organisational Sub-Committee Structure (Jan 2014)
- Accession of United Kingdom’s Veterinary Agency VMD (Jan 2014)
- Accession of Chinese Taipei’s TFDA and New Zealand’s Medsafe (Jan 2013)
PIC/S Executive Bureau

- Joey Gouws (South Africa / MCC), PIC/S Chairperson;
- Paul Hargreaves (UK / MHRA), PIC/S Deputy Chairman and Chair of the Sub-Committee on Budget, Risk and Audit (SCB);
- Helena Baião (Portugal / INFARMED IP), immediate former Chairperson;
- Boon Meow Hoe (Singapore / HSA), Chair of the Sub-Committee on Training (SCT);
- Andreas Krassnigg (Austria / AGES), Chair of the Sub-Committee on Expert Circles (SCEC);
- Jacques Morénas (France / ANSM), Chair of the Sub-Committee on Strategic Development (SCSD);
- Anne Hayes (Ireland / IMB), Chair of the Sub-Committee on Compliance (SCC);
- Paul Gustafson (Canada / HPFBI), Chair of the Sub-Committee on GM(D)P Harmonisation (SCH);
- Tor Gråberg (Sweden / MPA), Chair of the Sub-Committee on Communication (SC COM).
PIC/S Contacts

PIC/S Secretariat
14 rue du Roveray
CH - 1207 GENEVA

Tel: +41.22 738 92 16
Fax: +41.22 738 92 17
Email: info@picscheme.org
Web site: www.picscheme.org
Welcome to the PIC/S Website!

The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (jointly referred to as PIC/S) are two international instruments between countries and pharmaceutical inspection authorities, which provide together an active and constructive co-operation in the field of GMP.

PIC/S’ mission is “to lead the international development, implementation and maintenance of harmonised Good Manufacturing Practice (GMP) standards and quality systems of inspectorates in the field of medicinal products.”

This is to be achieved by developing and promoting harmonised GMP standards and guidance documents; training competent authorities, in particular inspectors; assessing (and reassessing)